Transcatheter aortic valve replacement (TAVR) is an alternative minimally invasive treatment option for patients with severe aortic stenosis who are not referred for surgical treatment. Today, up to 300,000 TAVR implantations have been performed worldwide. Short- and medium-term outcomes after TAVR are encouraging with significant reduction in rates of death. However, adverse events associated with TAVR have been reported, including annulus rupture, coronary occlusion, paravalvular leak (PVL), pacemaker implantation, vascular complications and stroke. Our goal is to develop a novel virtual TAVR system (VirtuTAVR) to assist clinicians with diagnostic and preventative strategies to prevent clinical adverse events. The VirtuTAVR system only requires pre-operative CT scans of a patient, which are now part of “standard-of-care” and routinely ordered for TAV patients. The system can display 3D aortic vasculature for TAVR planning and provide outcome prediction of the deployment of a TAVR device into an individual patient aortic root. The simulation output will be guidelines for appropriate access route selection, proper TAV sizing and positioning, and desired TAV expansion force inside a patient’s aortic root to avoid clinical adverse events.
* This project was funded by NIH SBIR and Connecticut Innovation SBIR Accelerator Funding. * The VirtuTAVR is not approved for investigational use or sale in the United States.